Promis Neurosciences INC Form 4 insider transactions

Michael S. Gordon reports a significant reduction in his beneficial ownership of ProMIS Neurosciences shares due to an asset assignment and management change.

Michael S. Gordon, a Director and 10% owner of ProMIS Neurosciences Inc., exercised a significant number of warrants at a reduced price and acquired additional warrants, increasing his indirect beneficial ownership.

Title 19 Promis, a director and 10% owner of ProMIS Neurosciences Inc., has substantially increased its beneficial ownership through the exercise of existing warrants at a reduced price and the acquisition of new warrants.

ProMIS Neurosciences Inc. Director and 10% Owner Michael S. Gordon reported a transfer of 93,223 common shares into a limited liability company in exchange for membership interests.

ProMIS Neurosciences Inc. Director Josh Mandel-Brehm was granted 20,000 stock options with an exercise price of $0.50, vesting by June 12, 2026.

ProMIS Neurosciences Inc. director Patrick D. Kirwin was granted 20,000 stock options with an exercise price of $0.50, vesting by June 12, 2026.

Madge K. Shafmaster, a Director at ProMIS Neurosciences Inc., was granted 20,000 stock options with an exercise price of $0.50, vesting by June 12, 2026.

ProMIS Neurosciences Inc. director William W. Wyman was granted 20,000 stock options with an exercise price of $0.50, vesting by June 2026, as reported in a recent SEC Form 4 filing.

ProMIS Neurosciences Inc. Director Eugene Williams has been granted 20,000 stock options with an exercise price of $0.50 per share, vesting on June 12, 2026.

Neil Cashman, Chief Scientific Officer and Director of ProMIS Neurosciences Inc., reports purchasing 15,000 common shares at $0.973 per share.

Max A. Milbury, Principal Accounting Officer of ProMIS Neurosciences Inc., was granted options to purchase 70,000 common shares.

Johanne Kaplan, Chief Development Officer at ProMIS Neurosciences, was granted stock options for 175,000 common shares.

ProMIS Neurosciences' Chief Scientific Officer, Neil Cashman, was granted 200,000 stock options on November 18, 2024, which vest over a 48-month period.

ProMIS Neurosciences' Chief Medical Officer, Larry Douglas Altstiel, was granted options to purchase 175,000 common shares.

Neil Warma, CEO of ProMIS Neurosciences, reports the acquisition of stock options in the company.

Director William Wyman acquired options to purchase 40,000 common shares of ProMIS Neurosciences Inc. on October 3, 2024.

Director Eugene Williams acquired options to purchase 40,000 common shares of Promis Neurosciences Inc. at an exercise price of $1.11, with vesting occurring over time.

Director Madge K. Shafmaster acquired options to purchase 40,000 common shares of ProMIS Neurosciences Inc. on October 3, 2024.

Josh Mandel-Brehm, a director of ProMIS Neurosciences Inc., acquired options to purchase 40,000 common shares of the company on October 3, 2024.

Director Patrick D. Kirwin acquired options to purchase 40,000 common shares of ProMIS Neurosciences Inc. at an exercise price of $1.11, according to a recent SEC filing.

Director Madge K. Shafmaster reports acquiring additional common shares of Promis Neurosciences Inc. through a series of transactions.

Michael S. Gordon, a director of ProMIS Neurosciences Inc., recently purchased shares of the company's common stock in multiple transactions.

Director Patrick Kirwin of ProMIS Neurosciences Inc. reports the acquisition of 10,000 common shares at $1.2492 per share.

Title 19 Promis acquired common shares and warrants in ProMIS Neurosciences through a private placement and conversion of preferred shares.

Michael S. Gordon, a director of ProMIS Neurosciences, acquired common shares and warrants through a private placement and conversion of preferred shares on July 31, 2024.

Jeremy M. Sclar, a director and 10% owner of ProMIS Neurosciences Inc., acquired common shares and warrants through a private placement and conversion of preferred shares on July 31, 2024.